专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140005269A1 POLYMERIC MATRIX OF POLYMER-LIPID NANOPARTICLES AS A PHARMACEUTICAL DOSAGE FORM 审中-公开
标题翻译：聚合物脂质纳米粒子作为药物剂型的聚合物
公开(公告)号：US20140005269A1
公开(公告)日：2014-01-02
申请号：US13989462
申请日：2011-11-28
申请人： Ndidi Ngwuluka , Viness Pillay , Yahya Essop Choonara , Lisa Claire Du Toit
发明人： Ndidi Ngwuluka , Viness Pillay , Yahya Essop Choonara , Lisa Claire Du Toit
IPC分类号： A61K47/32 , A61K31/198
CPC分类号： A61K47/32 , A61K9/2077 , A61K9/513 , A61K31/198
摘要： A pharmaceutical dosage form for the release of at least one pharmaceutically active ingredient is claimed. The pharmaceutical dosage form includes a polymer matrix, polymer-lipid nanoparticles incorporated within the matrix and the pharmaceutically active ingredient(s). The polymer matrix is formed from at least two crosslinked cationic and anionic polymers, such as Eudragit® E100 and sodium carboxymethlycellulose. It can also include a neutral polymer, such as one derived from locust bean. The polymer-lipid nanoparticles are formed from at least one polymer, such as Eudragit® E100 and/or chitosan, and at least one phospholipid, such as lecithin. The polymer(s) and phospholipid are crosslinking with a chelating agent, such as sodium tripolyphosphate. The active ingredient or ingredients can be any pharmaceutically active compound(s), and in particular poorly absorbed compounds such as levodopa for the treatment of Parkinson's disease.
摘要翻译：要求保护用于释放至少一种药物活性成分的药物剂型。药物剂型包括聚合物基质，掺入基质内的聚合物 - 脂质纳米颗粒和药物活性成分。聚合物基质由至少两种交联的阳离子和阴离子聚合物如Eudragit E100和羧甲基纤维素钠形成。它还可以包括一种中性聚合物，如从刺槐豆衍生的聚合物。聚合物 - 脂质纳米颗粒由至少一种聚合物如Eudragit E100和/或壳聚糖和至少一种磷脂如卵磷脂形成。聚合物和磷脂与螯合剂如三聚磷酸钠交联。活性成分或成分可以是任何药物活性化合物，特别是不良吸收的化合物，例如用于治疗帕金森病的左旋多巴。

IPRDB

热门服务

关于我们

友情链接

联系方式